Drosophila Models of Alzheimer's Disease Pathology

Drosophila melanogaster has emerged as a versatile in vivo platform for modelling key aspects of Alzheimer’s disease pathology. Through targeted expression of human amyloid-β peptides, mutant tau proteins or combinations of amyloid precursor protein and secretases, fly models recapitulate hallmark features of neurodegeneration, including extracellular plaque formation, intracellular tangle-like inclusions, synaptic dysfunction, motor and cognitive deficits, and reduced lifespan. The genetic tractability of Drosophila enables large-scale modifier screens that have identified kinases, phosphatases and cytoskeletal regulators as determinants of toxicity. Moreover, these models allow rapid assessment of cellular processes such as oxidative stress, mitochondrial dynamics, autophagy and proteasomal clearance in the context of amyloidogenic and tau-driven proteotoxicity. By visualising protein aggregation and propagation in live tissues, Drosophila studies have provided mechanistic insight into seeding cascades and cell-to-cell spread of pathology. Importantly, these models serve as cost-effective platforms for preclinical evaluation of small molecules, natural compounds and dietary interventions, bridging the gap between genetic discovery and therapeutic development in a wide range of biological contexts.

Research from Nature Portfolio

Recent studies have probed novel therapeutic strategies and mechanistic underpinnings of amyloid pathology. One investigation demonstrated that a stingless bee pollen extract rich in flavonoids and polyphenols confers significant neuroprotection in an Aβ-expressing fly. Treatment enhanced survival and locomotor performance, reduced histological markers of neurodegeneration and attenuated oxidative stress in the brain. These findings underscore the potential of antioxidant phytochemicals to modulate amyloid toxicity in vivo. In foundational work on amyloid propagation, experimental induction of small amounts of aggregation-competent Aβ42 in select neuronal clusters was shown to trigger widespread deposition of otherwise soluble Aβ40 throughout the fly brain. This seeding paradigm accelerated neurotoxicity and behavioural decline, offering a powerful genetic toolkit for interrogating modifiers of the amyloid cascade and for visualising the dynamics of aggregate spread.

Drosophila Models of Alzheimer's Disease Pathology publication trend

The graph below shows the total number of articles in drosophila models of alzheimer's disease pathology across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid-β (Aβ42): A 42-amino-acid peptide prone to aggregation, central to plaque formation in Alzheimer’s disease.

Transgenic Drosophila: Fruit flies genetically engineered to express human disease-related proteins for in vivo study.

Oxidative stress: An imbalance between reactive oxygen species production and antioxidant defences, leading to cellular damage.

Autophagy: A lysosome-mediated degradation pathway that clears damaged organelles and protein aggregates.

Seeding: The process by which preformed protein aggregates induce misfolding and aggregation of soluble monomers.

Proteotoxicity: Cellular dysfunction and death caused by accumulation of misfolded or aggregated proteins.

Neurodegeneration: Progressive loss of neuronal structure and function associated with disease states.

References

1. Icaritin greatly attenuates β‐amyloid‐induced toxicity in vivo. CNS Neuroscience & Therapeutics (2023).
2. A Novel Drosophila Model of Alzheimer’s Disease to Study Aβ Proteotoxicity in the Digestive Tract. International Journal of Molecular Sciences (2024).
3. Pathological Defects in a Drosophila Model of Alzheimer’s Disease and Beneficial Effects of the Natural Product Lisosan G. Biomolecules (2024).
4. Antioxidant and anti-Alzheimer's potential of Tetragonisca angustula (Jataí) stingless bee pollen. Scientific Reports (2024).
5. Seed-induced acceleration of amyloid-β mediated neurotoxicity in vivo. Nature Communications (2017).
6. Drosophila melanogaster as a model organism for Alzheimer’s disease. Molecular Neurodegeneration (2013).